DERMA SCIENCES langfristiges Topinvest!
noch auszugeben ca 4,6 Millionen
Bei den fast wöchentlich zu berichteten Owners, gehe ich davon aus, das mitlerweile alles an den Mann gebracht wurde?
http://www.ir.dermasciences.com/profiles/investor/...ngID=1&s=302
Bei einem Kurs von 10 Dollar, hätte Derma Sciences eine MK von 150 Millionen Dollar.
DSC 127 ist für jede Indication mindesten 1 Milliarde Wert?
Dieses Jahr soll die Phase 3 in Diabetic Foot Ulcers gestartet werden.
Desweiteren wird geprüft ob Studien in Narbenreduktion, Verbrennungen und Chronische Wunden gestartet werden.
Die Präsentation von der LHA Life Sciences & Medical Technologies Virtual Conference
ist wirklich sehr lesenswert(vor allem Slid 14 Potential U.S. Sales Ramp Up)
http://www.ir.dermasciences.com/profiles/investor/EmailCheck.asp
Also bei Zulassung in nur einer Indication minimum 100 Dollar pro Share....
Ich rechne hier aber mit einer Übernahme für lau...
Wollen wir mal hoffen das die Übernahme nicht kommt und bald ein Partner mit ner fetten Upfrontzahlung präsentirt wird?
Gruss
Bekommt er demnächst auch einen Posten bei DSCI?
http://b2i.api.edgar-online.com/EFX_dll/...Fv_4rwenE-9&ID=8490759
Wann treiben sie den Preis hoch, und bereiten die Firma für den Verkauf vor????
Conference call begins at 11:00 a.m. Eastern time today
Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and 12 months ended December 31, 2011. Highlights of the fourth quarter of 2011 and recent weeks include:
Net sales were $16.5 million, up 8% over the prior-year fourth quarter, while net sales for the year were $62.6 million, up 11% over 2010
Advanced wound care product sales were $4.5 million for the fourth quarter of 2011, up 23% and were $15.9 million for the year, up 37% over the prior year
Advanced wound care products accounted for 27% of net sales, up from 24% in the prior-year quarter
Traditional wound care product sales for the quarter were $12.1 million, up 4% from $11.7 million in the prior year quarter
Hired 10 advanced wound care sales representatives during the first quarter of 2012 for a total of 36 as of March 26th, well ahead of schedule
Positive meeting with the U.S. Food and Drug Administration (FDA) regarding preparations to begin Phase 3 trials with DSC127 for the treatment of diabetic foot ulcers
Fourth quarter 2011 net loss was $2.5 million, or $0.23 per share compared with $0.3 million, or $0.05 per share, in the prior year quarter as planned investments in sales force expansion and research and development added to expenses
http://www.ir.dermasciences.com/profiles/investor/...amp;Category=440
http://finance.yahoo.com/q/it?s=DSCI+Insider+Transactions
Derma Sciences, Inc. (the "Company") (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced the pricing of an underwritten registered direct offering of 2,125,000 shares of common stock at a price of $9.25 per share. The offering is expected to close on or about April 5, 2012. Piper Jaffray & Co. is acting as the sole underwriter of the offering.
Net proceeds from the sale of the shares of common stock, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $17.9 million. The Company plans to use the net proceeds from the offering for the continued development of DSC127 and for general corporate purposes.
When available, copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from the Securities and Exchange Commission at www.sec.gov, or from Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or email prospectus@pjc.com, or by telephone at (800) 747-3924.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This offering may be made only by means of a prospectus supplement and accompanying base prospectus.
http://www.ir.dermasciences.com/profiles/investor/...amp;Category=440
http://finance.yahoo.com/news/...es-acquires-long-term-113143297.html
-Advanced Wound Care Products up 52%; Represents 33% of Net Sales-
-DSC127 Drug Program on Track for Phase 3 Start by Year End-
Conference call begins at 11:00 a.m. Eastern time today
http://finance.yahoo.com/news/...eports-second-quarter-113000077.html
Novel Combination of MEDIHONEY® and XTRASORB® Hydrates Dry Wounds and Absorbs Fluid from Wounds that are Draining
http://finance.yahoo.com/news/...aunches-medihoney-hcs-113000429.html
http://finance.yahoo.com/news/...ces-track-begin-phase-113000927.html
-Net Sales up 24%, Advanced Wound Care Sales up 67%, Traditional Wound Care Sales up 9%-
-DSC127 Drug Program on Track for Phase 3 Start by Year End-
Conference call begins at 11:00 a.m. Eastern time today
http://finance.yahoo.com/news/...reports-third-quarter-123000442.html